Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Characteristics and clinical implications of leukemic stem cells

Richard Stone • 28 Nov 2022
ASH 2022
Leukemia

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, explains why leukemic stem cells (SCs) are difficult to eradicate and how this poses a challenge for current chemotherapy agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Steering committee: AbbVie; DSMB: Aptevo, Epizyme, Syntrix, Takeda; Advisory board: AvenCell, Cellularity, CTI Pharma, GSK, Kura Onc, Rigel; Focus group: BerGenBio; Grand rounds: Jazz

More from Richard Stone

2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023
2:31
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone • 21 Mar 2023
1:14
The potential of uproleselan in patients with AML
Richard Stone • 21 Mar 2023
1:57
Insights into the treatment of patients with FLT3-mutated AML & the role of maintenance therapy
Richard Stone • 21 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals